BSE Live
Dec 24, 16:01Prev. Close
1216.80
Open Price
1216.80
Bid Price (Qty.)
1208.00 (30)
Offer Price (Qty.)
1214.00 (447)
NSE Live
Dec 24, 15:55Prev. Close
1218.00
Open Price
1220.90
Bid Price (Qty.)
1211.40 (15)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Aurobindo Pharma (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 1,940.35 | 1,519.46 | 563.12 | 182.04 | 834.16 | |
| Net CashFlow From Operating Activities | 590.41 | 328.03 | 624.92 | 504.05 | 244.57 | |
| Net Cash Used In Investing Activities | -623.60 | -401.44 | -294.96 | -533.82 | -569.74 | |
| Net Cash Used From Financing Activities | 34.60 | -31.44 | -229.40 | -78.43 | 443.12 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 1.41 | -104.85 | 100.56 | -108.20 | 118.23 | |
| Cash And Cash Equivalents Begin of Year | 9.72 | 114.57 | 14.01 | 122.21 | 3.98 | |
| Cash And Cash Equivalents End Of Year | 11.13 | 9.72 | 114.57 | 14.01 | 122.21 |
19.12.2025
15.12.2025
04.12.2025
23.11.2025
Aurobindo Pharma incurring loss at China Plant; hopes to achieve break-even by Q4
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL